Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009;191:469–483. doi: 10.1007/978-3-540-68964-5_20

Modulating cGMP to Treat Lung Diseases

Hossein-Ardeschir Ghofrani 4,✉, Friedrich Grimminger 4
Editors: Harald H H W Schmidt1, Franz Hofmann2, Johannes-Peter Stasch3
PMCID: PMC7121669  PMID: 19089341

Abstract

Background: Nitric oxide (NO) is constitutively produced in the lung by NO-synthases. The main cellular sources of lung NO production are the vascular endothelium and the airway epithelia (Bohle et al. 2000; German et al. 2000; Ide et al. 1999). Local NO production contributes to regulation of pulmonary perfusion depending on alveolar ventilation to assure optimized ventilation/perfusion distribution (Grimminger et al. 1995). NO-synthase activity is regulated on transcriptional and post-translational redox-based modulation level. The common signaling pathway of endogenous vasodilators, such as nitric oxide, prostaglandins, and natriuretic peptides, engage cyclic nucleotides (cAMP and cGMP). These second messengers are mainly produced by activation of adenylate- and guanylate-cyclases, both membrane-bound and soluble (Beavo 1995). Phosphodiesterases (PDEs) represent a superfamily of enzymes, with PDE1 through PDE11 being currently known, that inactivate cyclic AMP and cyclic GMP, with different tissue distribution and substrate specificities (Ahn et al. 1991; Von Euler and Liljestrand. 1946). Because of stabilization of these second messengers, PDE inhibitors differentially regulate levels of cAMP and/or cGMP, depending on their selectivity profile. Recently, direct activators and stimulators of the sGC have been suggested as new therapeutic tools for the treatment of lung vascular disorders that might have even higher potency than PDE inhibitors or exogenously applied NO.

Keywords: Nitric Oxide, Nitric Oxide, Pulmonary Hypertension, Pulmonary Arterial Hypertension, PDE5 Inhibitor

Contributor Information

Harald H. H. W. Schmidt, Email: harald.schmidt@med.monash.edu.au

Franz Hofmann, Email: pharma@ipt.med.tu-muenchen.de.

Johannes-Peter Stasch, Email: johannes-peter.stasch@bayerhealthcare.com.

Hossein-Ardeschir Ghofrani, Email: ardeschir.ghofrani@innere.med.uni-giessen.de.

Friedrich Grimminger, Email: friedrich.grimminger@innere.med.uni-giessen.de.

References

  1. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000;84:E4. doi: 10.1136/heart.84.2.e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Agusti AG, Rodriguez-Roisin R. Effect of pulmonary hypertension on gas exchange. Eur Respir J. 1993;6:1371–1377. [PubMed] [Google Scholar]
  3. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol. 1991;308:191–197. doi: 10.1007/978-1-4684-6015-5_15. [DOI] [PubMed] [Google Scholar]
  4. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple iso-forms. Physiol Rev. 1995;75:725–748. doi: 10.1152/physrev.1995.75.4.725. [DOI] [PubMed] [Google Scholar]
  5. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC., Jr Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure. Circulation. 2003;107:686–689. doi: 10.1161/01.CIR.0000055737.15443.F8. [DOI] [PubMed] [Google Scholar]
  6. Bohle RM, Hartmann E, Kinfe T, Ermert L, Seeger W, Fink L. Cell type-specific mRNA quantitation in non-neoplastic tissues after laser-assisted cell picking. Pathobiology. 2000;68:191–195. doi: 10.1159/000055922. [DOI] [PubMed] [Google Scholar]
  7. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS. 2002;16:1568–1569. doi: 10.1097/00002030-200207260-00021. [DOI] [PubMed] [Google Scholar]
  8. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest. 1996;109:1545–1549. doi: 10.1378/chest.109.6.1545. [DOI] [PubMed] [Google Scholar]
  9. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, Rodman DM. Inhibition of cyclic 3′–5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996;97:172–179. doi: 10.1172/JCI118386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453–459. [PubMed] [Google Scholar]
  11. Egan JJ. New treatments for pulmonary fibrosis? Lancet. 1999;354:1839–1840. doi: 10.1016/S0140-6736(99)00347-5. [DOI] [PubMed] [Google Scholar]
  12. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and aug ments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation. 2004;110:2253–2259. doi: 10.1161/01.CIR.0000144469.01521.8A. [DOI] [PubMed] [Google Scholar]
  13. Francis SH, Chu DM, Thomas MK, Beasley A, Grimes K, Busch JL, Turko IV, Haik TL, Corbin JD. Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods. 1998;14:81–92. doi: 10.1006/meth.1997.0567. [DOI] [PubMed] [Google Scholar]
  14. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol. 1998;53:123–127. doi: 10.1124/mol.53.1.123. [DOI] [PubMed] [Google Scholar]
  15. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996;15:6863–6868. [PMC free article] [PubMed] [Google Scholar]
  16. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. YC-1 poten tiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol. 1998;54:962–967. doi: 10.1124/mol.54.6.962. [DOI] [PubMed] [Google Scholar]
  17. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pul monary arterial hypertension. N Engl J Med. 2005;353:2148–2157. doi: 10.1056/NEJMoa050010. [DOI] [PubMed] [Google Scholar]
  18. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phos phodiesterase activity. Br J Pharmacol. 1999;127:195–203. doi: 10.1038/sj.bjp.0702495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. German Z, Chambliss KL, Pace MC, Arnet UA, Lowenstein CJ, Shaul PW. Molecular basis of cell-specific endothelial nitric-oxide synthase expression in airway epithelium. J Biol Chem. 2000;275:8183–8189. doi: 10.1074/jbc.275.11.8183. [DOI] [PubMed] [Google Scholar]
  20. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002a;136:515–522. doi: 10.7326/0003-4819-136-7-200204020-00008. [DOI] [PubMed] [Google Scholar]
  21. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002b;360:895–900. doi: 10.1016/S0140-6736(02)11024-5. [DOI] [PubMed] [Google Scholar]
  22. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003a;42:158–164. doi: 10.1016/S0735-1097(03)00555-2. [DOI] [PubMed] [Google Scholar]
  23. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003b;167:1139–1141. doi: 10.1164/rccm.200210-1157BC. [DOI] [PubMed] [Google Scholar]
  24. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44:1488–1496. doi: 10.1016/j.jacc.2004.06.060. [DOI] [PubMed] [Google Scholar]
  25. Gopal VK, Francis SH, Corbin JD. Allosteric sites of phosphodiesterase-5 (PDE5). A po tential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem. 2001;268:3304–3312. doi: 10.1046/j.1432-1327.2001.02233.x. [DOI] [PubMed] [Google Scholar]
  26. Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, Seeger W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol. 1995;78:1509–1515. doi: 10.1152/jappl.1995.78.4.1509. [DOI] [PubMed] [Google Scholar]
  27. Hassoun PM, Filippov G, Fogel M], Donaldson C, Kayyali US, Shimoda LA, Bloch KD. Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2004;30:908–913. doi: 10.1165/rcmb.2003-0287OC. [DOI] [PubMed] [Google Scholar]
  28. Higenbottam T, Siddons T, Demoncheaux E. A therapeutic role for chronic inhaled nitric oxide? Lancet. 2000;356:446–447. doi: 10.1016/S0140-6736(00)02548-4. [DOI] [PubMed] [Google Scholar]
  29. Hillier SC, Graham JA, Hanger CC, Godbey PS, Glenny RW, Wagner WW., Jr Hypoxic vasoconstriction in pulmonary arterioles and venules. J Appl Physiol. 1997;82:1084–1090. doi: 10.1152/jappl.1997.82.4.1084. [DOI] [PubMed] [Google Scholar]
  30. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866–1870. doi: 10.1056/NEJM200006223422503. [DOI] [PubMed] [Google Scholar]
  31. Huai Q, Liu Y, Francis SH, Corbin JD, Ke H. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determi nant of inhibitor selectivity. J Biol Chem. 2004;279:13095–13101. doi: 10.1074/jbc.M311556200. [DOI] [PubMed] [Google Scholar]
  32. Ide H, Nakano H, Ogasa T, Osanai S, Kikuchi K, Iwamoto J. Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J Appl Physiol. 1999;87:1629–1636. doi: 10.1152/jappl.1999.87.5.1629. [DOI] [PubMed] [Google Scholar]
  33. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hyperten sion. Indian Heart J. 2002;54:404–409. [PubMed] [Google Scholar]
  34. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90:677–680. doi: 10.1016/S0002-9149(02)02586-9. [DOI] [PubMed] [Google Scholar]
  35. Li D, Zhou N, Johns RA. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol. 1999;277:L841–L847. doi: 10.1152/ajplung.1999.277.4.L841. [DOI] [PubMed] [Google Scholar]
  36. Li D, Laubach VE, Johns RA. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol. 2001;281:L369–L376. doi: 10.1152/ajplung.2001.281.2.L369. [DOI] [PubMed] [Google Scholar]
  37. Melot C, Lejeune P, Leeman M, Moraine JJ, Naeije R. Prostaglandin E1 in the adult res piratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis. 1989;139:106–110. doi: 10.1164/ajrccm/139.1.106. [DOI] [PubMed] [Google Scholar]
  38. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398–2403. doi: 10.1161/01.CIR.0000016641.12984.DC. [DOI] [PubMed] [Google Scholar]
  39. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066–2069. doi: 10.1161/01.CIR.0000099502.17776.C2. [DOI] [PubMed] [Google Scholar]
  40. Moncada I, Jara J, Subira D, Castano I, Hernandez C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol. 2004;46:357–360. doi: 10.1016/j.eururo.2004.04.025. [DOI] [PubMed] [Google Scholar]
  41. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol. 2003;160:719–727. doi: 10.1083/jcb.200211041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997;120:681–689. doi: 10.1038/sj.bjp.0700982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Oliver J, Webb DJ. Sildenafil for “blue babies”. Such unlicensed drug use might be justified as last resort. BMJ. 2002;325:1174. doi: 10.1136/bmj.325.7373.1174/a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820–824. doi: 10.7326/0003-4819-124-9-199605010-00006. [DOI] [PubMed] [Google Scholar]
  45. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med. 1998;24:631–634. doi: 10.1007/s001340050628. [DOI] [PubMed] [Google Scholar]
  46. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hy pertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160:600–607. doi: 10.1164/ajrccm.160.2.9810008. [DOI] [PubMed] [Google Scholar]
  47. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, Behr J, Kleber FX, Seeger W. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 2000;132:435–443. doi: 10.7326/0003-4819-132-6-200003210-00003. [DOI] [PubMed] [Google Scholar]
  48. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329. doi: 10.1056/NEJMoa020204. [DOI] [PubMed] [Google Scholar]
  49. Patole S, Travadi J. Sildenafil for “blue babies”. Ethics, conscience, and science have to be balanced against limited resources. BMJ. 2002;325:1174. doi: 10.1136/bmj.325.7373.1174. [DOI] [PubMed] [Google Scholar]
  50. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000;343:1342. doi: 10.1056/NEJM200011023431814. [DOI] [PubMed] [Google Scholar]
  51. Radermacher P, Santak B, Becker H, Falke KJ. Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology. 1989;70:601–606. doi: 10.1097/00000542-198904000-00008. [DOI] [PubMed] [Google Scholar]
  52. Reichenberger F, Voswinckel R, Enke B, Rutsch M, Fechtali EE, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007;30:922–927. doi: 10.1183/09031936.00039007. [DOI] [PubMed] [Google Scholar]
  53. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399–405. doi: 10.1056/NEJM199302113280605. [DOI] [PubMed] [Google Scholar]
  54. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–117. doi: 10.1056/NEJM199701093360207. [DOI] [PubMed] [Google Scholar]
  55. Sastry BK, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR, Kumar DN. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. 2002;54:410–414. [PubMed] [Google Scholar]
  56. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149–1153. doi: 10.1016/j.jacc.2003.10.056. [DOI] [PubMed] [Google Scholar]
  57. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with im provement in gas exchange. J Pharmacol Exp Ther. 2000;292:512–520. [PubMed] [Google Scholar]
  58. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS. 2001;15:1747–1748. doi: 10.1097/00002030-200109070-00026. [DOI] [PubMed] [Google Scholar]
  59. Singh B, Gupta R, Punj V, Ghose T, Sapra R, Grover DN, Kaul U. Sildenafil in the manage ment of primary pulmonary hypertension. Indian Heart J. 2002;54:297–300. [PubMed] [Google Scholar]
  60. Stasch JP, Becker EM, onso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212–215. doi: 10.1038/35065611. [DOI] [PubMed] [Google Scholar]
  61. Stasch JP, Schmidt P, onso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773–783. doi: 10.1038/sj.bjp.0704778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Straub A, Stasch JP, onso-Alija C, et-Buchholz J, Ducke B, Feurer A, Furstner C. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett. 2001;11:781–784. doi: 10.1016/S0960-894X(01)00073-7. [DOI] [PubMed] [Google Scholar]
  63. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol. 1997;320:161–166. doi: 10.1016/S0014-2999(96)00911-9. [DOI] [PubMed] [Google Scholar]
  64. Von Euler US, Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand. 1946;12:301–320. doi: 10.1111/j.1748-1716.1946.tb00389.x. [DOI] [Google Scholar]
  65. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet. 1993;342:961–962. doi: 10.1016/0140-6736(93)92004-D. [DOI] [PubMed] [Google Scholar]
  66. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther. 2002;71:398–402. doi: 10.1067/mcp.2002.123554. [DOI] [PubMed] [Google Scholar]
  67. Wegener JW, Nawrath H. Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur J Pharmacol. 1997;323:89–91. doi: 10.1016/S0014-2999(97)00111-8. [DOI] [PubMed] [Google Scholar]
  68. Weissmann N, Voswinckel R, Tadic A, Hardebusch T, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F. Nitric oxide (NO)-dependent but not NO-independent guanylate cy-clase activation attenuates hypoxic vasoconstriction in rabbit lungs. Am J Respir Cell Mol Biol. 2000;23:222–227. doi: 10.1165/ajrcmb.23.2.3935. [DOI] [PubMed] [Google Scholar]
  69. Weissmann N, Grimminger F, Olschewski A, Seeger W. Hypoxic pulmonary vasoconstric-tion: a multifactorial response? Am J Physiol Lung Cell Mol Physiol. 2001;281:L314–L317. doi: 10.1152/ajplung.2001.281.2.L314. [DOI] [PubMed] [Google Scholar]
  70. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218–1222. doi: 10.1161/hc3601.096826. [DOI] [PubMed] [Google Scholar]
  71. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM. YC-1 inhibited human platelet aggrega tion through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol. 1995;116:1973–1978. doi: 10.1111/j.1476-5381.1995.tb16400.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Beneficial effects of phosphodi-esterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation. 2003;107:234–237. doi: 10.1161/01.CIR.0000050653.10758.6B. [DOI] [PubMed] [Google Scholar]
  73. Zimmermann AT, Calvert AF, Veitch EM. Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J. 2002;32:424–426. doi: 10.1046/j.1445-5994.2002.00258.x. [DOI] [PubMed] [Google Scholar]

Articles from cGMP: Generators, Effectors and Therapeutic Implications are provided here courtesy of Nature Publishing Group

RESOURCES